Everything below concerns reconstitution. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-25. Where a claim depends on a specific study, the study is described rather than over-claimed.
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
Activity is mediated mainly through the growth hormone secretagogue receptor, now generally called the ghrelin receptor or GHS-R1a. Binding at this G-protein-coupled receptor triggers phospholipase C signaling, calcium mobilization, and release of growth hormone from pituitary somatotrophs. Reports describe less pronounced stimulation of adrenocorticotropic hormone and prolactin compared with earlier secretagogues such as hexarelin or GHRP-6. Selectivity figures vary between assay systems, so the degree of separation from other secretagogues is an area of ongoing comparison rather than a fixed constant.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
| Property | Value | Notes |
|---|---|---|
| 分子式 | C38H49N9O5 | 五肽，C 端酰胺化 |
| 分子量 | 约 711.85 g/mol | 游离碱形式 |
| 外观 | 白色至类白色冻干粉 | 研究用材料的常见形态 |
| 溶解性 | 溶于水及 DMSO 等极性溶剂 | 建议现配现用 |
| 储存温度 | -20 °C 或更低 | 干燥、避光、限制冻融次数 |
Peptides such as ipamorelin are subject to chemical and physical degradation. Hydrolysis of peptide bonds, oxidation of susceptible residues, and aggregation are common pathways that reduce purity over time. The rate of these processes depends on temperature, moisture, pH, and the number of freeze-thaw cycles a sample undergoes. Because the compound is typically handled as a lyophilized powder, controlling moisture during storage is a central concern. Degradation products can be detected with separation techniques that resolve the parent peptide from related impurities.
Lyophilized material is generally stored frozen and protected from light and moisture. Typical recommendations place dry powder at temperatures well below freezing, while reconstituted solutions are kept cold and used within a defined window. Repeated freezing and thawing should be avoided because it can promote aggregation and loss of material. The choice of solvent matters as well; compatibility with the intended diluent should be checked before preparation. These handling practices aim to preserve both the quantity and the integrity of the peptide.
Lyophilized ipamorelin is generally held at minus twenty degrees Celsius or colder, protected from light and moisture. In solution the peptide is less stable, and degradation proceeds through hydrolysis of the amide backbone, oxidation of the histidine residue, and aggregation. Repeated freeze-thaw cycles accelerate these processes, so dividing material into single-use aliquots before freezing is common practice in research settings. Buffered formulations near neutral pH tend to show the slowest degradation, while strongly acidic or basic conditions raise hydrolysis rates. Stability data specific to ipamorelin are sparse, and much guidance is extrapolated from other short peptides.
Quality control for research-grade ipamorelin is not governed by a single harmonized pharmacopeial monograph, so certificates of analysis vary between suppliers. Common tests include appearance, solubility, water content, peptide content by quantitative amino acid analysis, and residual counterion measurement. Independent verification by an outside laboratory is often used to confirm identity and purity claims. Salt form, counterion content, and residual solvent levels are frequently unspecified, which complicates direct comparison between lots and leaves reproducibility partly unresolved.
Identity and purity assessment of ipamorelin relies mainly on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometers, a wavelength where the peptide backbone absorbs. Mass confirmation is typically obtained by electrospray ionization mass spectrometry or by liquid chromatography coupled to mass spectrometry, comparing the observed mass with the calculated value. Amino acid analysis and peptide mapping after enzymatic digestion can confirm the sequence. Impurity profiles include deletion peptides, truncated fragments, and oxidation products, reported as relative area percentages.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
== Biosynthesis == Patellamide A originates from a ribosomal peptide, making it a member of the RiPP superfamily of natural products. This was determined after genome sequencing of P. didemi showed a lack of non ribosomal peptide synthetases. The biosynthetic gene cluster for patellamide A contains the genes patA, patB, patC, patD, patE, patF and patG. These genes, when introduced into E. coli, cause the production of patellamide A, definitively confirming their responsibility for patellamide A biosynthesis. The gene patE encodes the precursor peptide that contains the primary sequences of patellamides A and C. It has been proposed by Schmidt et al. that this prepatellamide is heterocyclized to form the oxazoline and thiazoline rings by PatD2. It is proposed that PatG1 is subsequently involved in oxidizing the thiazoline rings to the thiazole rings found in patellamide A. The peptide is then cleaved, possibly by PatA or PatG2, and cyclized, the cyclization is likely aided by adenylation by PatD1, forming the two cyclic peptides, patellamides A and C. Although all the amino acids used in the production of patellamide A are L-amino acids, some of the amino acids found in natural patellamide A are the D-epimers. It is proposed that epimerization of these amino acids occurs spontaneously. This was determined by comparison to a similar system, lissoclinamide 7.
"Annotated bibliography for tritium". Alsos Digital Library. Washington and Lee University. Archived from the original on 14 May 2006. Retrieved 3 March 2022. "Nuclear Data Evaluation Lab". Review of Risks from Tritium (Report). London, UK: Health Protection Agency. November 2007. RCE-4. Archived from the original on 17 May 2013. Retrieved 3 March 2022. Bergeron, Kenneth D. (17 September 2004). Tritium on Ice: The dangerous new alliance of nuclear weapons and nuclear power. MIT Press. ISBN 978-0-262-26172-2. "Tritium production and recovery in the United States in FY2011". Fissile Materials. February 2010. "Tritium removal mass transfer coefficient". ans.org.
Technetium-99m (Tc-99m) can be readily detected in the body by medical equipment because it emits 140.5 keV gamma rays (these are about the same wavelength as emitted by conventional X-ray diagnostic equipment), and its half-life for gamma emission is six hours (meaning 94% of it decays to 99Tc in 24 hours). Besides, it emits virtually no beta radiation, thus keeping radiation dosage low. Its decay product, 99Tc, has a relatively long half-life (211,000 years) and emits little radiation. The short physical half-life of 99mTc and its biological half-life of 1 day with its other favourable properties allows scanning procedures to collect data rapidly and keep total patient radiation exposure low. Chemically, technetium-99m is selectively concentrated in the stomach, thyroid, and salivary glands, and excluded from cerebrospinal fluid; combining it with perchlorate abolishes its selectiveness.
Insulin is an endogenous hormone, which is produced by the pancreas. The insulin protein has been highly conserved across evolutionary time, and is present in both mammals and invertebrates. The insulin/insulin-like growth factor signalling pathway (IIS) has been extensively studied in species including nematode worms (e.g.C. elegans), flies (Drosophila melanogaster) and mice (Mus musculus). Its mechanisms of action are highly similar across species. Both type 1 diabetes and type 2 diabetes are marked by a loss of pancreatic function, though to differing degrees. People who are affected with diabetes are referred to as diabetics. Many diabetics require an exogenous source of insulin to keep their blood sugar levels within a safe target range. In 1916, Nicolae C. Paulescu (1869–1931) succeeded in developing an aqueous pancreatic extract that normalized a diabetic dog. In 1921, he published 4 papers in the Society of Biology in Paris centering on the successful effects of the pancreatic extract in diabetic dogs. Research on the Role of the Pancreas in Food Assimilation by Paulescu was published in August 1921 in the Archives Internationales de Physiologie, Liège, Belgium. Initially, the only way to obtain insulin for clinical use was to extract it from the pancreas of another creature. Animal glands were obtainable as a waste product of the meatpacking industry. Insulin was derived primarily from cows (bovine) (Thorburn Brailsford Robertson (Australia); Eli Lilly and Company (USA)) and pigs (porcine) (Nordisk Insulinlaboratorium).
Sources: en.wikipedia.org
The process of photosynthesis provides the main input of free energy into the biosphere, and is one of four main ways in which radiation is important for plant life. The radiation climate within plant communities is extremely variable, in both time and space. In the early 20th century, Frederick Blackman and Gabrielle Matthaei investigated the effects of light intensity (irradiance) and temperature on the rate of carbon assimilation.
release of pituitary hormones synthesis of pituitary hormones release of stored pituitary hormones hyperplasia hypertrophy The anterior pituitary produces prolactin, GH, TSH, ACTH, FSH, and LH. Fifteen to 20 percent of corticotroph cells produce ACTH. The targets are the adrenal glands, adipocytes and melanocytes. Three to five percent of thyrotroph cells produce TSH. Ten to 15 percent are gonadotrophic and produce LH and FSH. Forty to 50 percent are somatotrophic and produce GH, in childhood in particular. Ten to 15 percent are lactotrophic and produce prolactin.
It is impossible to suppress the demand for drugs." He quoted Helen Clark, former prime minister of New Zealand and head of the Global Commission on Drug Policy: "The total elimination of drugs? Dream on, there's never been a time in human history where human beings haven't resorted to some kind of substances that will take them out of their current reality for whatever reason."
Sources: en.wikipedia.org
=== Serotonin reuptake inhibition === All SSRIs block the reuptake of serotonin through the serotonin transporter (SERT). This occurs in various anatomical sites, including the presynaptic terminals of serotonergic neurons in the central and peripheral nervous systems, enteric neurons and epithelial cells in the gastrointestinal tract, the pulmonary endothelium, and platelets. In the central nervous system, the majority of released serotonin is taken up by SERT. When this process is blocked, it stays in the synaptic gap longer than it normally would, and may repeatedly stimulate the receptors of the postsynaptic cell. In the short run, this leads to an increase in signaling across synapses in which serotonin is the primary neurotransmitter. On chronic dosing, the increased occupancy of post-synaptic serotonin receptors signals the pre-synaptic neuron to synthesize and release less serotonin. Serotonin levels within the synapse drop, then rise again, ultimately leading to downregulation of post-synaptic serotonin receptors. Other, indirect effects may include increased norepinephrine output, increased neuronal cyclic AMP levels, and increased levels of regulatory factors such as BDNF and CREB.
Sargramostim, sold under the brand name Leukine among others, is a recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) that functions as an immunostimulator. It is administered via intravenous infusion or via subcutaneous injection.
With the announcement of GPT-2 in 2019, OpenAI originally planned to keep the source code of their models private citing concerns about malicious applications. After OpenAI faced public backlash, however, it released the source code for GPT-2 to GitHub three months after its release. OpenAI did not publicly release the source code or pretrained weights for the GPT-3 model. At the time of GPT-3's release, GPT-2 was still the most powerful open source language model in the world. 2022 also saw the rise of larger and more powerful models under licenses of varying openness including Meta's OPT. The Open Source Initiative consulted experts over two years to create a definition of "open-source" that would fit the needs of AI software and models. The most controversial aspect relates to data access, since some models are trained on sensitive data which can't be released. In 2024, they published the Open Source AI Definition 1.0 (OSAID 1.0). It requires full release of the software for processing the data, training the model and making inferences from the model. For the data, it only requires access to details about the data used to train the AI so others can understand and re-create it. On August 22, 2022, open-source text-to-image model Stable Diffusion was first released. In 2023, Meta's weights-available Llama 1 and 2, and Mistral AI's open-weight Mistral and Mixtral models were first released, along with MosaicML's smaller open-source models. The release of the Llama models was a milestone in generating interest in open-weight and open-source models.
=== Manufacturing of biotextiles === Before the production of biotextiles, monofilament structures were typically produced using extrusion techniques, where a single continuous filament was drawn from a polymer melt. These monofilaments can then be used directly or further processed into various biomedical devices, such as sutures, meshes, and vascular grafts. Biotextiles are created using multiple techniques, such as knitting, weaving, and braiding, to form the fabric-like structures used in biomedical applications. The three primary spinning techniques traditionally employed in fiber manufacturing are wet-spinning, dry-spinning, and melt-spinning.
Sources: en.wikipedia.org
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。
公开资料中它主要以研究用肽的形式出现，未获主要监管机构批准用于治疗。可得材料通常标注仅供研究使用。任何临床用途的宣称都缺少监管依据。
序列中的 Aib 与 D-2-Nal 等非天然残基可提高对肽酶的抵抗能力，并影响受体结合的构象。这类修饰在合成肽设计中较为常见。它们也使常规氨基酸分析需要额外步骤才能确认序列。
Aib 即 α-氨基异丁酸，是一种非蛋白质源氨基酸，其侧链为两个甲基。它在肽链中倾向于诱导螺旋构象并限制骨架的柔性。这种刚性被认为有助于抵抗蛋白酶切割。